Search results
Results from the WOW.Com Content Network
The property is now owned by DFS Advisors, and is under long-term lease to Novartis. The complex, which includes the factory building, a power plant, and a modern (2003) parking garage, occupies most of an entire city block bounded by Massachusetts Avenue, Cross Street, Albany Street, and Lansdowne Street.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, [2] [1] [3] employing approximately 5,400 people. Medpace's mission statement is "to accelerate the global development of safe and effective medical therapeutics" through its high science and disciplined operating approach that leverages local, regulatory, and deep therapeutic expertise across ...
For the fiscal year 2022, Novartis reported earnings of US$6.955 billion, with an annual revenue of US$50.545 billion, a decrease of 71 percent over the previous fiscal cycle. Novartis shares traded at over $80.56 per share, and its market capitalization was valued at $198.34B as of 31 January 2023. [141] [142]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Novartis Gene Therapies, until 2020 known as AveXis, is a biotechnology company that develops treatments for rare neurological genetic disorders. It was founded in Dallas , Texas , United States in 2012 by John Carbona after reorganizing a company called BioLife Cell Bank founded by David Genecov and John Harkey.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis. [ 4 ] [ 5 ] In April 2016, the company announced a name change from Arrowhead Research Corporation to Arrowhead Pharmaceuticals, Inc. [ 6 ]
The New York City Economic Development Corporation's Early Stage Life Sciences Funding Initiative and venture capital partners, including Celgene, General Electric Ventures, and Eli Lilly, committed a minimum of US$100 million to help launch 15 to 20 ventures in life sciences and biotechnology in 2014, [6] and in January 2018, the City of New ...